Relay Therapeutics, Inc. Increase (Decrease) in Accounts Receivable
Relay Therapeutics, Inc. (RLAY) reported Increase (Decrease) in Accounts Receivable of -$306.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-02-26
- Relay Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2023-12-31 was -$211.00K, a 424.62% decline year-over-year.
- Relay Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2023-09-30 was $133.00K.
- Relay Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2023-06-30 was -$208.00K, a 1194.74% decline year-over-year.
- Relay Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2023-03-31 was -$20.00K.
- Relay Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2023 was -$306.00K.
- Relay Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2022 was -$97.00K.
- Relay Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2021 was -$74.68M, a 199.57% decline from fiscal 2020.
- Relay Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2020 was $75.00M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$211.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$78.00K derived: sum of 2 quarters · filed 2026-02-26 | -$286.00K derived: sum of 3 quarters · filed 2026-02-26 | -$306.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | $133.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$75.00K derived: sum of 2 quarters · filed 2024-11-06 | -$95.00K 10-Q · filed 2024-11-06 | -$30.00K derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | -$208.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$228.00K 10-Q · filed 2024-08-06 | -$163.00K derived: sum of 3 quarters · filed 2025-02-26 | -$210.00K derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | -$20.00K 10-Q · filed 2024-05-02 | $45.00K derived: sum of 2 quarters · filed 2025-02-26 | -$2.00K derived: sum of 3 quarters · filed 2025-02-26 | $17.00K derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $65.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $18.00K derived: sum of 2 quarters · filed 2025-02-26 | $37.00K derived: sum of 3 quarters · filed 2025-02-26 | -$97.00K 10-K · filed 2025-02-26 |
| 2022-09-30 | -$47.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$28.00K derived: sum of 2 quarters · filed 2023-11-02 | -$162.00K 10-Q · filed 2023-11-02 | -$563.00K derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $19.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$115.00K 10-Q · filed 2023-08-08 | -$516.00K derived: sum of 3 quarters · filed 2024-02-22 | $9.00K derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$134.00K 10-Q · filed 2023-05-04 | -$535.00K derived: sum of 2 quarters · filed 2024-02-22 | -$10.00K derived: sum of 3 quarters · filed 2024-02-22 | $189.00K derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | -$401.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $124.00K derived: sum of 2 quarters · filed 2024-02-22 | $323.00K derived: sum of 3 quarters · filed 2024-02-22 | -$74.68M 10-K · filed 2024-02-22 |
| 2021-09-30 | $525.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $724.00K derived: sum of 2 quarters · filed 2022-11-03 | -$74.28M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $199.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$74.80M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | -$75.00M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $75.00M 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |